^
    21h
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=300, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | N=117 --> 300
    Enrollment open • Enrollment change
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    5d
    A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=213, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    6d
    A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer (clinicaltrials.gov)
    P2, N=57, Recruiting, Memorial Sloan Kettering Cancer Center | N=99 --> 57
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    2141-V11
    8d
    Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Providence Health & Services | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • CDX-1140
    1m
    SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
    P1, N=106, Terminated, Shattuck Labs, Inc. | Completed --> Terminated; Development discontinued
    Trial termination
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    2ms
    Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). (PubMed, J Immunother Cancer)
    The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4+ T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines.
    P1/2 data • Journal • IO biomarker • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD40 (CD40 Molecule)
    |
    BRAF V600E • BRAF mutation • BRAF V600
    |
    CDX-1140 • Hiltonol (poly-ICLC)
    2ms
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Pennsylvania | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)
    2ms
    CROCOBIL: Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P2/3, N=160, Not yet recruiting, UNICANCER
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitazalimab (ADC-1013)
    2ms
    Phase I Study of APX005M in Pediatric Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Nov 2025 --> Jun 2026
    Trial completion date
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    sotigalimab (PYX-107)
    3ms
    Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNF1901 in the treatment of advanced malignant tumor patients (ChiCTR2500111722)
    P1, N=82, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1 trial
    3ms
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, M.D. Anderson Cancer Center | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    3ms
    A Study of KK2269 in Adult Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=101, Recruiting, Kyowa Kirin Co., Ltd. | N=71 --> 101 | Trial completion date: Dec 2027 --> Mar 2029 | Trial primary completion date: Dec 2027 --> Mar 2029
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    docetaxel